Effects of Carnosine on the Toxicity of Doxorubicin in Rabbits and Mice

Pteridines

Volumn 14, Issue 3, 2003, Pages 94-101

  Zieba, Remigiusz ^a   Czarnecka, Elzbieta ^a   Wagrowska Danilewicz, Malgorzata ^a   Dzielska Olczak, Malgorzata ^a   Graczyk, Julita ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardio protection; Cardiotoxicity; Carnosine; Doxorubicin; Haemodynamic parameters; Histopathological changes

Indexed keywords

ANTIOXIDANT; CARNOSINE; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART INDEX; HEART MUSCLE CELL; HEART PROTECTION; HEART RATE; HEMODYNAMICS; HISTOPATHOLOGY; MALE; MEAN ARTERIAL PRESSURE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TOXICITY; VASCULAR RESISTANCE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0348042097     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2003.14.3.94     Document Type: Article

References (48)

1. Ragab, A.H., Sutow, W.W., Komp, D.M., Starling, K.A., Lyon, G.M., George, S. (1975) Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. Cancer 36, 1567-1576.
2. Ogura, M. (2001) Adriamycin (doxorubicin). Cancer and chemotherapy 28, 1331-1338.
3. Ferrans, V.J. (1978) Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62, 955-961.
4. Ferrans, V.J., Clark, Jr, Zhang, J., Yu, Z.X., Herman, E.H. (1997) Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 39, 928-937.
5. Gille, L., Kleiter, M., Willmann, M., Nohl, H. (2002) Paramagnetic species in the plasma of dogs with lymphoma prior to and after treatment with doxorubicin. An ESR study. Biochem Pharmacol 64, 1737-1744.
6. Barnabe, N., Zastre, J.A., Venkataram, S., Hasinoff, B.B. (2002) Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 33, 266-275.
7. Speyer, J., Wasserheit, C. (1998) Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol 25, 525-537.
8. Muggia, F.M. (1994) Cytoprotection: concepts and challenges. Support Care Cancer 2, 377-379.
9. Horinishi, H., Grillo, M., Margolis, F.L. (1978) Purification and characterization of carnosine synthetase from mouse olfactory bulbs. J Neurochem 31, 909-919.
10. Margolis, F.L., Grillo, M., Hempstead, J., Morgan, J.I. (1987) Monoclonal antibodies to mammalian carnosine synthetase. Neurochem 48, 593-600.
11. Herman, E.H., Ferrans, V.J. (1993) Timing of treatment with ICR-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 32, 445-449.
12. Podesta, A., Della-Torre, P., Pinciroli, G., Iatropoulos, M.J., Brughera, M., Mazue, G. (1994) Evaluation of 4′-iodo-4′ -deoxydoxorubicin-induced cardiotoxicity in two experimental rat models. Toxicol Pathol 22, 68-71.
13. Dziegiel, P., et al. (2002) Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxicol Pathol 53, 433-439.
14. Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., Leeuweburgh, C. (2002) Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity and Bcl2:Bax ratio. Cancer Res 62, 4592-4598.
15. Seifert, C.F., Nesser, M.E., Thompson, D.F. (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28, 1063-1072.
16. Lacko, A., Wlodarska, I., Zymlinski, R., Mazur, G., Wrobel, T., Gisterek, I. (2002) Cardiac toxicity in cancer therapy. Pol Merkuriusz Lek 13, 79-85.
17. Imondi, A.R., Della-Torre, P., Mazue, G., et al. (1996) Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56, 4200-4204.
18. Dorr, R.T. (1996) Cytoprotective agents for anthracyclines. Semin Oncol 23, 23-34.
19. Swain, S.M., Whalez, F.S., Gerber, M.C., et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15, 1318-1332.
20. Swain, S.M. (1998) Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 25, 43-47.
21. Lopez, M., Vici, P. (1998) European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity. Semin Oncol 25, 55-60.
22. Catino, A., Cruciia, E., Latorre, A., Sambiasi, D., Calabrese, P., Lorusso, V. (2003) Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. Oncol Rep 10, 163-167.
23. Bagchi, D., Ray, S.D., Bagchi, M., Preuss, H.G., Stohs, S.J. (2002) Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract. Indian J Exp Biol 40, 717-726.
24. Liu, X., Chen, Z., Chua, C.C., et al. (2002) Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol 283, H254-63.
25. Nagasawa, T., Yonekura, T., Nishizawa, N., Kitts, D.D. (2001) In vitro and in vivo inhibition of muscle lipid and protein oxidation by carnosine. Mol Cell Biochem 225, 29-34.
26. Klebanov, G.I., Teselkin, Yu, O., Babenkova, I.V., Lyubitsky, O.B., Rebrova, O.Yu., Boldyrev, A.A. (1998) Effect of carnosine and its components on free-radical reactions. Membr Cell Biol 12, 89-99.
27. Tamba, M., Torreggiani, A. (1999) Hydroxyl radical scavenging by carnosine and Cu(II)-carnosine complexes: a pulse-radiolysis and spectroscopic study. Int J Radiat Biol 75, 1177-1188.
28. Kang, J.H., Kim, K.S., Choi, S.Y., Kwon, H.Y., Won, M.H., Kang, T.C. (2002) Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu,Zn-superoxide dismutase modification. Biochim Biophys Acta 1570, 89-96.
29. Fontana, M., Pinnen, F., Lucente, G., Pecci, L. (2002) Prevention of peroxynitrite-dependent damage by carnosine and related sulphonamido pseudodipeptides. Cell Mol Life Sci 59, 546-551.
30. Kim, K.S., Choi, S.Y., Kwon, H.Y., Won, M.H., Kang, T.C., Kang, J.H. (2002) The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. Biochimie 84, 625-631.
31. Aldini, G., Granata, P., Carini, M. (2002) Detoxification of cytotoxic alpha, beta-unsaturated aldehydes by carnosine: characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrom 37, 1219-1228.
32. Burcham, P.C., Kaminskas, L.M., Fontaine, F.R., Petersen, D.R., Pyke, S.M. (2002) Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 181-182, 229-36.
33. Hipkiss, A.R., Brownson, C., Bertani, M.F., Ruiz, E., Ferro, A. (2002) Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci 959, 285-294.
34. McFarland, G.A., Holliday, R. (1994) Retardation of the senescence of cultured human diploid fibroblasts by camosine. Exp Cell Res 212, 167-175.
35. Hipkiss, A.R., Brownson, C. (2000) Carnosine reacts with protein carbonyl groups: another possible role for the anti-ageing peptide? Biogerontology 1, 217-223.
36. Kang, K.S., Yun, J.W., Lee, Y.S. (2002) Protective effect of L-carnosine against 12-O-tetrade-canoylphorbol-13-acetate- or hydrogen peroxide-induced apoptosis on v-myc transformed rat liver epithelial cells. Cancer Lett 178, 53-62.
37. Roberts, P.R., Zaloga, G.P. (2000) Cardiovascular effects of carnosine. Biochemistry 65, 856-861.
38. Babizhayev, M.A., Deyev, A.I., Yermakova, V.N., et al. (2002) Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs in Rand D 3, 87-103.
39. Suzuki, H., Mori, M., Seto, K., et al. (2001) Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils. Aliment Pharmacol Ther 15, 715-725.
40. Kashimura, H., Suzuki, K., Hassan, M., et al. (1999) Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 13, 483-487.
41. Kato, S., Tanaka, A., Ogawa, Y., et al. (2001) Effect of polaprezinc on impaired healing of chronic gastric ulcers in adjuvant-induced arthritis rats - role of IGF-1. Med Sci Monit 7, 20-25.
42. Katayama, S., Nishizawa, K., Hirano, M., Yamamura, S., Momose, Y. (2000) Effect of polaprezinc on healing of acetic acid-induced stomatitis in hamsters. J Pharm Pharm Sci 3, 114-117.
43. Stvolinsky, S.L., Dobrota, D. (2000) Antiischemic activity of carnosine. Biochemistry 65, 849-855.
44. Chez, M.G., Buchanan, C.P., Aimonovitch, M.C., et al. (2002) Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 17, 833-837.
45. Blake, D., Way, D., Trigg, L., McGrath, B. (1994) Regional blood flow effects of dopexamine versus enalaprilat during propofol anaesthesia in rabbits with experimental chronic heart failure. Cardiovasc. Res 28, 710-714.
46. Tamaki, N., Ikeda, T., Fujimoto, S., Mizutani, N. (1985) Carnosine as a histidine source: transport and hydrolysis of exogenous carnosine by rat intestine. J Nutr Sci Vitaminol 31, 607-618.
47. Gardner, M.L., Illingworth, K.M., Kelleher, J., Wood, D. (1991) Intestinal absorption of the intact peptide carnosine in man and comparison with intestinal permeability to lactulose. J Physiol 439, 411-422.
48. Hama, T., Tamaki, N., Miyamoto, F. (1976) Intestinal absorption of beta-alnine, anserine and carnosine in rats. J Nutr Sci Vitaminol 22, 147-157.